ethris GmbH is a company headquartered in Planegg, Germany, that engages in researching and developing biotechnology. The firm was founded by Christian Plank and Carsten Rudolph. Carsten Rudolph is currently the CEO of the company.\nThe company says this about itself: Ethris has paved a new path from genes to therapeutic proteins using its proprietary, non-immunogenic messenger RNA technology platform to discover, design and develop innovative therapies. With more than a decade as an mRNA pioneer, we are a global leader in delivering stabilized mRNAs directly to the respiratory system via optimized formulation and nebulization technologies. We are rapidly approaching in vivo proof of concept for generating therapeutic antibodies against COVID-19 in the lung while advancing our pipeline of immuno-modulation and mRNA-based protein replacement therapies with the ultimate goal of improving patients? lives.

4D Molecular Therapeutics, Inc. operates as a clinical stage biotherapeutics company, which engages in the design, development, and commercialization of transformative gene therapeutic products for serious unmet medical conditions. It offers products for ophthalmology, cardiology, and pulmonology. The company was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

Omnispirant Ltd. is a private company headquartered in Ireland. The firm develops gene therapy which transforms to respiratory medicine.

Emulate, Inc. owns and operates Organs-on-Chips platform which acts as an automated human bioemulation platform for mimicking true human physiology. The firm's product responses to medicines, chemicals, and diseases can be predicted. The company was founded by James Coon, Donald Ingber and Geraldine Hamilton in July 2014 and is headquartered in Cambridge, MA.

Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. - Identify and assess research projects with commercial potential. - Protect the intellectual property of the Institute and its scientists. - Create business relationships and license the Institute’s inventions and technologies to the industry. - Channel funding from industry to research projects. For further information please contact Tamir Huberman, CIO and Head of Marketing

Translate Bio, Inc. engages in the research and development of therapeutic drugs. It focuses on developing medicines to treat diseases caused by protein or gene dysfunction. Its lead product candidate, MRT5005 is designed for the treatment of cystic fibrosis. The company was founded by Arthur M. Krieg and Jeannie T. Lee in 2011 and is headquartered in Lexington, MA.

ReCode Therapeutics is a genetic medicines company that specializes in mRNA and gene correction therapeutics. Its selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.

Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA.

Biovitrum is an international pharmaceutical company that markets specialist pharmaceuticals in several regions globally. Using its expertise and experience Biovitrum takes scientific innovation to patients with significant unmet medical need. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within our prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company has revenues of approximately SEK 1.2 billion and around 400 employees. The company head office is located in Sweden. In 2009, Biovitrum merged with [Swedish Orphan](/organization/swedish-orphan), and the combined company has subsequently been rebranded as Swedish Orphan Biovitrum.

Mect Corp. manufactures cooling systems and self-developed dispensers. Its products include micro dispensers, micro dosing devices, adhesive dosing devices, gluing devices and micro pumps. The company was founded on August 12, 1981 and is headquartered in Osaka, Japan.

Eyestem is a cell therapy company founded by a top-class management team consisting of clinical trial, cell therapy and ophthalmology experts. It also boasts a world class advisory board and we have built collaborations with pioneers and leaders in the space. Our long-term vision is to create a global and scalable cell therapy platform to treat incurable diseases. We are developing a cell therapy platform to produce consistent, quality products over the next few years, concentrating on in vitro efficacy and safety.

Anthrogenesis, based in Cedar Knolls, New Jersey, is a biotherapeutics company that has developed proprietary methods for collecting, processing and storing stem cells and other valuable biomaterials derived from human placental tissue. Anthrogenesis is focused on developing and delivering therapies using stem cells sourced from human placental tissue to treat cancers and immunological, metabolic and inflammatory diseases. Anthrogenesis has demonstrated that the human placenta is an abundant source of biotherapies, including early stage stem cells and other biomaterials for organ and tissue repair. Anthrogenesis also operates Lifebank, a state-licensed blood bank that banks stem cell transplant units derived from placental tissue and in some cases, blood from the umbilical cord that is collected immediately after birth.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Academisch Ziekenhuis Maastricht operates as medical research centre. The company is headquartered in Maastricht, the Netherlands.

Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the University Hospital of Lund, the company is pioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC). These stem cells have unique properties for applications in regenerative medicine. Amniotics has also an, by Läkemedelsverket (MPA in Sweden), approved GMP (Good Manufacturing Practice) manufacturing facility to produce Advanced therapy medicinal products (ATMPs). With the GMP facilities operational since 2020, Amniotics is now moving into clinical trials with the leading drug candidate, PulmoStem™ and is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs.

Nitric Solutions, Inc. operates as a biotechnology company. It develops prophylactic and therapeutic treatment for infectious diseases. The company was founded by Chris Miller in 1993 and is headquartered in North Vancouver, Canada.

12th Man Technologies, Inc. is a private company headquartered in Garden Grove, CA, that develops healthcare technologies for pulmonary and critical care medicine.

Anhui Youjin Guanhua New Material Technology Co., Ltd., established on 2017-08-24, Business scope includes precious metals(gold,silver,platinum,Palladium)and non-ferrous metal mines(copper,lead,aluminum,magnesium)mining,to smelt,Deep Processing,Sales and Supply Chain Collaboration;sulfuric acid;Metal and non-metal scrap and scrap processing;Research and development of special processes and technologies for special resources and new materials,to promote;Consulting and System Integration Services;R&D and application of materials in the field of new energy;other electricity production(Except for projects prohibited by the state and projects subject to pre-approval).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Mitoimmune Therapeutics, Inc. is a company headquartered in Seoul, the South Korea. The firm develops drugs for treating inflammatory diseases and cancers. It was founded in 2018 by Sun-Ha Kim, he has been the CEO since the company founding.\nThe company says this about itself: MIT-001 is a novel class of anti-inflammatory and anti-necrotic agent, specifically scavenging ROS in the mitochondria. This action mechanism of MIT-001 is expected to effectively suppress massive inflammation like oral mucositis occurring in the necrotic ulcers of oral mucous via removing excessive mitochondrial ROS, a major contributing factor in the CCRT-induced inflammation and necrosis. MitoImmune is a leading biotech company focusing on the development of mitochondrial therapeutics providing a breakthrough for life-threatening diseases based on its proprietary structural platform technology, which was scientifically verified through more than 40 published papers. MitoImmune is seeking to expand its R&D pipelines to chronic inflammatory disorders and neurodegenerative diseases.